This article is more than 5 years old. Information may no longer be current.
Bacterin announces patent for new BMP-2 product
Click Here to Manage Email Alerts
Bacterin International Holdings recently announced the United States Patent and Trademark Office has issued the company U.S. Patent No. 8,992,964, entitled “Process for Demineralization of Bone Matrix with Preservation of Natural Growth Factors.”
The patent covers certain demineralized bone matrixes containing minimum levels of bone morphogenetic protein-2 (BMP-2) — a protein that is included in Bacterin’s OsteoSponge product line, according to a company press release.
The OsteoSponge allows for the allograft to become compressible while maintaining the spectrum of native growth factors inherent to bone. According to the company, clinical investigators have shown fusion rates greater than 97% in peer-reviewed, published studies. Bacterin was the first company to commercialize a compressible demineralized bone matrix sponge marketed specifically for its handling characteristics, osteoconductive architecture and osteoinductive properties for orthopedic bone grafting applications, according to the release.
Bacterin has pending continuing applications in the United States to pursue protection on other aspects of its bone demineralization technology.
Reference: www.bacterin.com.